President Trump’s executive order invoking the Defense Production Act to secure domestic supplies of glyphosate has fractured the Make America Healthy Again coalition, pitting the movement’s health-first identity against the agricultural priorities of the administration it helped elect. Robert F. Kennedy Jr., who spent years litigating against the herbicide, is now backing the production push, drawing sharp criticism from MAHA activists who warn the move contradicts the movement’s founding principles. The rift arrives as a cluster of recent peer-reviewed research strengthens the case that glyphosate poses risks well beyond what U.S. regulators have acknowledged.
Trump’s Executive Order Ignites a Coalition Crisis
The executive order, signed in mid-February 2026, directed federal agencies to use the Defense Production Act to ensure domestic supply of both phosphorus and glyphosate for American farmers, according to Reuters reporting. The decision framed the herbicide as a matter of food security, but it collided head-on with a constituency that had rallied around removing synthetic chemicals from the food supply. MAHA organizers had spent years arguing that the United States could strengthen its food system by reducing reliance on inputs like glyphosate, not by declaring them essential to national defense.
Kennedy’s endorsement of the plan stunned allies who had treated his anti-pesticide record as a litmus test for the movement’s credibility. The backlash was immediate. An unsigned post from MAHA leadership urged supporters to trust Trump’s reasoning and to push the administration to help farmers break free from regulatory constraints, according to Politico coverage. That attempt at damage control only deepened the split: activists read it as an admission that the order conflicted with the MAHA agenda, paired with a request to look the other way, and some warned that the coalition’s grassroots energy could evaporate if the White House appeared to side with chemical manufacturers over parents worried about exposure.
Rat Tumors, Heart Risk, and the Weight of New Evidence
The political fight is playing out against a backdrop of accumulating science that challenges the safety consensus around glyphosate. A long-term study published in Environmental Health exposed Sprague-Dawley rats to glyphosate from gestational day 6 through 104 weeks and found dose-related increases in tumors across multiple organ sites. The doses used in that study were mapped to the European Union’s acceptable daily intake of 0.5 mg/kg/day and the EU’s no-observed-adverse-effect level of 50 mg/kg/day, meaning the tumor signals appeared at exposure thresholds that regulators currently treat as safe. Researchers at George Mason University, part of the Global Glyphosate Study consortium, reported observing “early onset and early mortality for a number of rare malignant cancers, including leukemia, liver, ovary and nervous system cancers, in humans,” and noted that the GGS had previously published a pilot study showing endocrine and reproductive toxicity in rats at doses intended to reflect current human exposures.
Beyond cancer, a separate peer-reviewed analysis using U.S. adult biomonitoring data found an inverse association between urinary glyphosate levels and cardiovascular health as measured by the American Heart Association’s Life’s Essential 8 metrics. That relationship was non-linear, suggesting that even moderate exposure levels may track with worse heart health outcomes, though the observational design limits firm causal conclusions. A large meta-analysis aggregating 1,282 observations across 121 studies on non-target animal toxicity reported sublethal effects and stronger toxicity signals in aquatic and marine animals, including impaired growth and behavior, but the same review flagged publication bias in the existing literature, a caveat that complicates any sweeping ecological claims. For MAHA activists, these converging lines of evidence reinforce their argument that the administration is doubling down on a chemical whose risk profile is still being rewritten in real time.
EPA’s Regulatory Limbo on Glyphosate
The federal regulatory picture offers little clarity. The EPA’s 2020 interim decision on glyphosate, which found the chemical “not likely to be carcinogenic,” was challenged in court. The Ninth Circuit vacated the human health portion of that decision, and the agency subsequently withdrew the remaining portions of the interim ruling. That withdrawal left the registration review process unfinished, with proposed interim decision materials and responses to public comments on human health, ecological risk, and benefits assessments still compiled on the agency’s glyphosate docket but without a binding conclusion. As a result, the nation’s most widely used herbicide continues to be applied under an older approval framework while regulators rework their analysis.
The gap between the EPA’s stated position and the World Health Organization’s classification of glyphosate as “probably carcinogenic” has persisted for years, fueling public confusion. A retracted study on glyphosate and Roundup earlier this year renewed concerns about the integrity of the evidence base on both sides of the debate, according to an Associated Press account of the controversy. The EPA has also taken the position that product labels claiming glyphosate is “known to cause cancer” are false and misleading under federal pesticide labeling law, a stance that has put the agency at odds with state-level warning requirements and with advocates who argue that precautionary language is warranted while long-term risks remain under review.
Health Agencies’ Cautious Messaging Meets Grassroots Alarm
Federal health agencies have tried to thread a needle between acknowledging potential hazards and avoiding definitive statements that the science has not yet settled. The Agency for Toxic Substances and Disease Registry notes that glyphosate has been associated with eye and skin irritation, nausea, and, in cases of very high exposure, more serious outcomes such as lung damage, but concludes that people with low-level environmental contact are less likely to develop respiratory effects. That relatively restrained language contrasts sharply with the rhetoric of MAHA organizers, who often frame glyphosate as an urgent, systemic threat to children’s health and fertility and point to the newest animal and biomonitoring studies as justification for aggressive phaseouts.
This divergence in tone has become a flashpoint inside the coalition. Some MAHA-aligned physicians and scientists argue that official toxicology summaries remain too narrow, focusing on acute poisoning and obvious irritation rather than the subtle endocrine, cardiovascular, and developmental endpoints emerging in recent research. Others worry that overstating the risks could backfire if future reviews moderate the current concerns, undermining public trust in the movement’s broader health agenda. The Defense Production Act order has forced these internal tensions into the open by tying the coalition’s identity to a concrete policy decision on a single, controversial chemical.
Strategic Crossroads for the Make America Healthy Again Movement
For MAHA, the glyphosate dispute is more than a technical argument over toxicology; it is a test of whether a health-focused faction can maintain influence inside a political project that also prioritizes deregulation and farm productivity. Some organizers warn that if the coalition swallows the Defense Production Act order, it will signal that health concerns are subordinate to industrial policy, weakening their leverage on future fights over vaccines, food additives, and environmental contaminants. Others counter that abandoning Trump over a single herbicide could squander a rare opportunity to reshape federal health agencies and that the movement should instead push for tighter exposure limits, better monitoring, and support for farmers transitioning away from glyphosate-dependent systems.
The administration, for its part, appears to be betting that concerns about food prices and supply chain stability will outweigh unease about herbicide exposure among its base. Yet the scientific uncertainties, regulatory limbo, and visible fractures within MAHA suggest that the political costs of that bet are still unfolding. As new studies probe glyphosate’s links to cancer, cardiovascular disease, and ecological harm, and as the EPA works toward a new registration review, the coalition will have to decide whether to double down on its founding promise to “make America healthy” or to accommodate an industrial strategy that treats contested chemicals as indispensable. How MAHA resolves that dilemma may determine whether it remains a distinct force in national health debates or is absorbed into a more conventional battle over farm policy and federal regulation.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
